Tennessee Oncology - MURFREESBORO - SCRI - PPDS

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Acute myeloid leukaemia
• Chronic myeloid leukaemia
• Myelodysplastic syndromes

Closed trials

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source